Condition

Prostatic Neoplasms, Castration-Resistant clinical trials and research

• 13Clinical trials
• 20Countries

Newest Prostatic Neoplasms, Castration-Resistant clinical trials

All recruiting trials (13)

• Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer

  This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.

  Recruiting Lithuanian University of Health Sciences · Kaunas · NCT07863986

• FX-111 safety and pharmacokinetics in metastatic castration-resistant prostate cancer

  This study tests whether FX-111 is safe and can help treat metastatic castration-resistant prostate cancer in adult men.

  Recruiting at 7 sites Phase 1 Flare Therapeutics Inc. · Los Angeles, California and 9 other locations · NCT07719361

• Fractionated Stereotactic Radiotherapy Plus Second-Generation Antiandrogen in oligometastatic castration-resistant prostate cancer

  This study tests whether adding SBRT to a second-generation antiandrogen helps men with oligometastatic, castration-resistant prostate cancer see better outcomes.

  Recruiting at 6 sites Phase 2 Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic · Zaragoza, Aragon and 14 other locations · NCT07717268

• Pluvicto real-world use in metastatic castration-resistant prostate cancer

  This real-world study tests how well Pluvicto works in men with metastatic castration-resistant prostate cancer in the US and Germany.

  Recruiting Novartis · East Hanover, New Jersey · NCT07697989

• Real-world patterns and outcomes for mCRPC patients who have had ARPI, taxane, and 177Lu-PSMA-617

  This real-world study tests how patients with metastatic castration-resistant prostate cancer, who have already received an ARPI, a taxane, and 177Lu-PSMA-617, fare in US practice using PRECISION data.

  Recruiting Novartis · East Hanover, New Jersey · NCT07677267

• Real-world patterns and outcomes in metastatic castration-resistant prostate cancer

  This study tests how patients with metastatic castration-resistant prostate cancer are treated and how they fare in real-world U.S. practice using the PRECISION data platform.

  Recruiting Novartis · East Hanover, New Jersey · NCT07677254

• Pasritamig plus docetaxel versus docetaxel for metastatic castration‑resistant prostate cancer

  This trial tests whether adding pasritamig to standard docetaxel chemotherapy helps men with metastatic castration-resistant prostate cancer stay progression-free on scans longer than docetaxel alone.

  Recruiting at 165 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 164 other locations · NCT07225946

• Using 18F-Fluciclovine PET/CT to Predict Outcomes of Prostate Cancer Therapy

  This study is testing if special imaging can help predict how well a new prostate cancer treatment works for patients with advanced disease.

  Recruiting Phase 4 VA Greater Los Angeles Healthcare System · Los Angeles, California · NCT06706921

• Combination of Gedatolisib and Darolutamide for Advanced Prostate Cancer

  This study is testing a new combination of two drugs, gedatolisib and darolutamide, to see if they can help men with advanced prostate cancer feel better and improve their treatment outcomes.

  Recruiting at 5 sites Phase 1/2 Celcuity Inc · Detroit, Michigan and 12 other locations · NCT06190899

• Evaluating HTL0039732 for Advanced Solid Tumours

  This study is testing a new drug called HTL0039732, alone and with another treatment, to see if it can help people with advanced solid tumors by boosting their immune response against cancer.

  Recruiting at 6 sites Phase 1/2 Cancer Research UK · Cambridge and 5 other locations · NCT05944237

• Comparing treatment strategies for advanced prostate cancer

  This study is testing if a personalized treatment plan that includes taking breaks from hormone therapy can help men with advanced prostate cancer live better and longer compared to taking the medication every day.

  Recruiting at 19 sites Phase 2 Leiden University Medical Center · Albury, New South Wales and 18 other locations · NCT05393791

• Using 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA to identify and treat advanced prostate cancer

  This study is testing a new treatment using a special drug for men with advanced prostate cancer that hasn't responded to other hormone therapies to see if it can help manage their disease better.

  Recruiting at 7 sites Phase 1/2 Clarity Pharmaceuticals Ltd · Stanford, California and 6 other locations · NCT04868604

• Tulmimetostat treatment for advanced solid tumors and lymphomas

  This study is testing a new treatment called Tulmimetostat to see if it can help people with advanced solid tumors and lymphomas feel better and fight their cancer.

  Recruiting at 43 sites Phase 1/2 Novartis · Tampa, Florida and 79 other locations · NCT04104776

Related topics

Quick answers

How many Prostatic Neoplasms, Castration-Resistant clinical trials are recruiting right now?

13, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 20 countries. The most sites are in United States (9 trials), Spain (4 trials), United Kingdom (4 trials), France (3 trials), Australia (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 4, Phase 2: 2, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →